Compare SAH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | NUVB |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1997 | N/A |
| Metric | SAH | NUVB |
|---|---|---|
| Price | $92.12 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $78.25 | $11.38 |
| AVG Volume (30 Days) | 253.5K | ★ 9.0M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $9,951,630,000.00 | N/A |
| Revenue This Year | $4.61 | $203.82 |
| Revenue Next Year | $4.16 | $58.18 |
| P/E Ratio | $51.00 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $54.11 | $2.15 |
| 52 Week High | $99.02 | $9.75 |
| Indicator | SAH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 57.60 |
| Support Level | $60.00 | $5.26 |
| Resistance Level | N/A | $6.06 |
| Average True Range (ATR) | 3.44 | 0.42 |
| MACD | 0.76 | -0.01 |
| Stochastic Oscillator | 64.73 | 44.49 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 111 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025's revenue was $15.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.